APPLICATION NOTE »
Circulating Tumor Cells (CTCs) Enumeration Overcomes Limitations with other Blood-Based Cancer Detection Methods
The Genesis System for CTC Enumeration
The lack of reproducibility and sensitivity with legacy technologies has limited the clinical adoption of circulating tumor cells (CTCs) for cancer monitoring. The Genesis System was developed by Celsee, Inc. to address the shortcomings of single-cell analysis including CTC isolation and enumeration.
Download the Application Note
See how the Genesis System can help you get the most out of CTCs with better detection and monitoring.
To learn more, download the application note covering the following topics:
❯ Limitations of CTC analysis with legacy systems
❯ ctDNA vs. CTCs
❯ How the Genesis System improves CTC enumeration
❯ The Genesis System Workflow
❯ Downstream CTC analyses that can be performed on the Genesis System
❯ Other single-cell applications available on the Genesis System
